Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAB-301 in healthy adults
NCT02788188Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- May 2016
- Primary completion
- Apr 2018
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of sab-301 in Middle East respiratory syndrome (MERS) (7 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Number of Participants Having Adverse Events at 90 days. Started May 2016; status: completed.
02
Drugs
sab-301
03
Conditions
Middle East respiratory syndrome (MERS)
Beyond the preview
Go deeper on NCT02788188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02788188.